Factor VIII assays in treated hemophilia A patients
| Autor: | Lasne, Dominique, Pouplard, Claire, Nougier, Christophe, Eschwège, Valérie, Le Cam Duchez, Véronique, Proulle, Valérie, Smahi, Motalib, Harzallah, Ines, Voisin, Sophie, Toulon, Pierre, Sobas, Frédéric, Galinat, Hubert, Flaujac, Claire, Ternisien, Catherine, Jeanpierre, Emmanuelle, Duchez, Véronique Le Cam |
|---|---|
| Přispěvatelé: | Hémostase, Inflammation, Thrombose (HITH - U1176 Inserm - CHU Bicêtre), Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hospices Civils de Lyon (HCL), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'Hémostase Vasculaire [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), CH eaubonne montmorency, Service Hématologie, Mulhouse, Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA)-Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Pasteur [Nice] (CHU), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Centre Hospitalier de Versailles André Mignot (CHV), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut d'Hématologie-Transfusion, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
030213 general clinical medicine
medicine.medical_specialty congenital hereditary and neonatal diseases and abnormalities Hemophilia A Gastroenterology World health 03 medical and health sciences Collaborative group 0302 clinical medicine Internal medicine hemic and lymphatic diseases medicine Humans In patient Monitoring Physiologic Factor VIII Plasma samples medicine.diagnostic_test Chronometric and chromogenic assays Chromogenic substrate assay [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology General Medicine Hematology Prognosis 3. Good health Clinical Practice Coagulation Blood Coagulation Tests Blood Chemical Analysis Partial thromboplastin time |
| Zdroj: | Annales de Biologie Clinique Annales de Biologie Clinique, John Libbey Eurotext, 2019, 77 (1), pp.53-65. ⟨10.1684/abc.2019.1413⟩ |
| ISSN: | 0003-3898 |
| DOI: | 10.1684/abc.2019.1413⟩ |
| Popis: | International audience; Replacement therapy with plasma-derived or recombinant FVIII (pdFVIII or rFVIII) concentrates is the standard of treatment in patients with hemophilia A. The reference method used for measuring factor VIII (FVIII:C) levels in patients treated by FVIII concentrates is the chromogenic substrate assay (CSA). However, the one-stage clotting assay (OSA) is predominantly used in current clinical practice, but this method depends on the activated partial thromboplastin time (APTT) reagent and the coagulation analyzer used, and wide variations in the measurements of FVIII recovery have been reported with some factor concentrates. The French study group on the biology of hemorrhagic diseases (a collaborative group of the GFHT and MHEMO network) presents a review of the literature and proposals for the monitoring of FVIII:C levels in treated hemophilia A patients. The use of CSA calibrated with a plasma reference tested against the current FVIII WHO (World Health Organization) International Standard is recommended for the monitoring of patients treated with pdFVIII or rFVIII including extended half-life (EHL) rFVIII. OSA are adequate for the monitoring of patients treated with pdFVIII or with most of rFVIII concentrates. However, preliminary comparison with CSA is mandatory before measuring FVIII:C by OSA in patients treated by Refacto AF®. For rFVIII-EHL, OSA are only acceptable for Elocta®. Great caution is therefore required when measuring FVIII:C levels by OSA in patients substituted by other EHL-rFVIII. Indeed, most of recent studies reported data obtained with spiked plasmas, which deserve to be confirmed on plasma samples collected in treated patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|